Follow The Filings

PMN ProMIS Neurosciences

ProMIS Neurosciences earnings company data as of 4:48 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — -1.28 —
Rev — — —

Insider trades

Open-market buys and sales by PMN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PMN insider trades
  • $8.7M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Johanne Kaplan Chief Development Officer
    Buy
    $30K 2,280 shares at $13.30 +58% to stake
    Traded Aug 5 Filed Aug 7
  2. Patrick D. Kirwin Director
    Buy
    $45K 4,000 shares at $11.33 +613% to stake
    Traded Apr 22 Filed Apr 23
  3. Eugene Williams Director
    Buy
    $49K 2,000 shares at $24.40 +19% to stake
    Traded Mar 5 Filed Mar 6
  4. Eugene Williams Director
    Buy
    $92K 4,000 shares at $23.11 +63% to stake
    Traded Mar 2–4 Filed Mar 4
  5. Johanne Kaplan Chief Development Officer
    Buy
    $25K 1,629 shares at $15.35 +71% to stake
    Traded Feb 19 Filed Feb 23
  6. Slanix Paul Alex Director, +4 joint filers
    Buy
    $8.5M 700,741 shares at $12.13 +289% to stake
    Traded Feb 3 Filed Feb 5

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
8-K 7.01,8.01,9.01
8-K 5.02,5.07,9.01
SCHEDULE 13G —
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
DEF 14A
DEFA14A
SCHEDULE 13G —
8-K 2.02,9.01
10-K
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.